302 related articles for article (PubMed ID: 22294456)
21. Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity.
Rossi M; Young JW
J Immunol; 2005 Aug; 175(3):1373-81. PubMed ID: 16034072
[TBL] [Abstract][Full Text] [Related]
22. Plasmacytoid dendritic cells in tolerance.
Gehrie E; Van der Touw W; Bromberg JS; Ochando JC
Methods Mol Biol; 2011; 677():127-47. PubMed ID: 20941607
[TBL] [Abstract][Full Text] [Related]
23. Potent Bidirectional Cross-Talk Between Plasmacytoid Dendritic Cells and γδT Cells Through BTN3A, Type I/II IFNs and Immune Checkpoints.
Girard P; Ponsard B; Charles J; Chaperot L; Aspord C
Front Immunol; 2020; 11():861. PubMed ID: 32435249
[TBL] [Abstract][Full Text] [Related]
24. Understanding dendritic cells and their role in cutaneous carcinoma and cancer immunotherapy.
Yanofsky VR; Mitsui H; Felsen D; Carucci JA
Clin Dev Immunol; 2013; 2013():624123. PubMed ID: 23606870
[TBL] [Abstract][Full Text] [Related]
25. Dendritic cell biology and its role in tumor immunotherapy.
Wang Y; Xiang Y; Xin VW; Wang XW; Peng XC; Liu XQ; Wang D; Li N; Cheng JT; Lyv YN; Cui SZ; Ma Z; Zhang Q; Xin HW
J Hematol Oncol; 2020 Aug; 13(1):107. PubMed ID: 32746880
[TBL] [Abstract][Full Text] [Related]
26. Antigen presentation by dendritic cells and their significance in antineoplastic immunotherapy.
Bodey B; Siegel SE; Kaiser HE
In Vivo; 2004; 18(1):81-100. PubMed ID: 15011756
[TBL] [Abstract][Full Text] [Related]
27. Murine spleen contains a diversity of myeloid and dendritic cells distinct in antigen presenting function.
Hey YY; O'Neill HC
J Cell Mol Med; 2012 Nov; 16(11):2611-9. PubMed ID: 22862733
[TBL] [Abstract][Full Text] [Related]
28. Artificial antigen-presenting cells for use in adoptive immunotherapy.
Turtle CJ; Riddell SR
Cancer J; 2010; 16(4):374-81. PubMed ID: 20693850
[TBL] [Abstract][Full Text] [Related]
29. Dendritic cell therapy in cancer treatment; the state-of-the-art.
Sadeghzadeh M; Bornehdeli S; Mohahammadrezakhani H; Abolghasemi M; Poursaei E; Asadi M; Zafari V; Aghebati-Maleki L; Shanehbandi D
Life Sci; 2020 Aug; 254():117580. PubMed ID: 32205087
[TBL] [Abstract][Full Text] [Related]
30. [Antitumor cellular immunotherapy: the breakthrough of dendritic cells].
Angevin E; André F; Zitvogel L
Bull Cancer; 2000 Jan; 87(1):107-15. PubMed ID: 10673639
[No Abstract] [Full Text] [Related]
31. Dendritic cell-based immunotherapy.
Berger TG; Schultz ES
Curr Top Microbiol Immunol; 2003; 276():163-97. PubMed ID: 12797448
[TBL] [Abstract][Full Text] [Related]
32. Harnessing dendritic cells for immunotherapy.
Delamarre L; Mellman I
Semin Immunol; 2011 Feb; 23(1):2-11. PubMed ID: 21377379
[TBL] [Abstract][Full Text] [Related]
33. Natural killer-dendritic cell cross-talk in cancer immunotherapy.
Kalinski P; Mailliard RB; Giermasz A; Zeh HJ; Basse P; Bartlett DL; Kirkwood JM; Lotze MT; Herberman RB
Expert Opin Biol Ther; 2005 Oct; 5(10):1303-15. PubMed ID: 16197336
[TBL] [Abstract][Full Text] [Related]
34. The role of dendritic cells in tumor microenvironments and their uses as therapeutic targets.
Kim CW; Kim KD; Lee HK
BMB Rep; 2021 Jan; 54(1):31-43. PubMed ID: 33298246
[TBL] [Abstract][Full Text] [Related]
35. Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines.
Saxena M; Bhardwaj N
Curr Opin Immunol; 2017 Aug; 47():35-43. PubMed ID: 28732279
[TBL] [Abstract][Full Text] [Related]
36. Dysfunction of antigen processing and presentation by dendritic cells in cancer.
Bandola-Simon J; Roche PA
Mol Immunol; 2019 Sep; 113():31-37. PubMed ID: 29628265
[TBL] [Abstract][Full Text] [Related]
37. The importance of being a pDC in antiviral immunity: the IFN mission versus Ag presentation?
Haeryfar SM
Trends Immunol; 2005 Jun; 26(6):311-7. PubMed ID: 15922947
[TBL] [Abstract][Full Text] [Related]
38. Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network.
Bodey B; Bodey B; Kaiser HE
In Vivo; 1997; 11(4):351-70. PubMed ID: 9292303
[TBL] [Abstract][Full Text] [Related]
39. Generation of antigen-specific cytotoxic T lymphocytes using a leukemic plasmacytoid dendritic cell line as antigen presenting cells.
Yamahira A; Narita M; Nakamura T; Watanabe N; Kaji M; Taniguchi T; Hashimoto S; Furukawa T; Toba K; Aizawa Y; Kuzushima K; Takahashi M
Leuk Res; 2011 Jun; 35(6):793-9. PubMed ID: 21216464
[TBL] [Abstract][Full Text] [Related]
40. [Dendritic cells for cancer immunotherapy].
Kakimi K; Kondo A; Matsushita H
Nihon Rinsho; 2012 Dec; 70(12):2130-5. PubMed ID: 23259385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
